cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

June 1, 2005 - AGM Statement

Cyprotex (LSE: CRX) announces that, at the Annual General Meeting held on Wednesday 1 June 2005, all the resolutions proposed were duly passed and the financial statements were approved.

Robert Morrisson Atwater, Chairman and CEO of Cyprotex Plc, said: "I would like to express my satisfaction with regards to the reorganisation of the Company in 2004. 2005 has started in line with management's best expectations.

"In addition, we are at an advanced stage of negotiations on a significant new contract with a major US biopharmaceutical group. This new deal would be in line with our aim to develop further, both geographically and by contract size."

For further information:

Cyprotex PLC
Robert Morrisson Atwater, Chairman & Chief Executive Officer
Tel: +44 1625 505 152
ir@cyprotex.com
www.cyprotex.com

Code Securities
Charles Walker
Tel: +44 (0) 20 7024 2000
cew@codesecurities.com
www.codesecurities.com

Media Enquires:

Abchurch Communications
Heather Salmond / Margaret Strinati
Tel: +44 (0) 20 7398 7700
heather.salmond@abchurch-group.com
www.abchurch-group.com

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.